Skip to main content
. 2013 Dec 20;16(12):632–638. [Article in Chinese] doi: 10.3779/j.issn.1009-3419.2013.12.03

2.

BIM基因多态性与EGFR-TKI治疗疗效的关系

Relationship between BIM gene polymorphism and therapeutic efficacy of tyrosine kinase inhibitor

Therapeutic evaluation BIM no polymorphism BIM polymorphism χ2 P
CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; ORR: objective response rate; DCR: disease control rate.
CR 0 0 0 0
PR 33 3 2.746 0.098
SD 44 9 0.006 0.981
PD 25 9 2.931 0.087
ORR 32.4% 14.3% 2.746 0.098
DCR 75.5% 57.1% 2.931 0.087